|
|
Professor Jinshi’s experience in treating chronic liver disease |
CHEN Quan1 SUN Lixia1 ZHOU Nan2 YANG Haoran1 LIU Li’na1 SHI Huilian1 |
1.Department of Infectious Diseases, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province, Nanjing 210029, China;
2.Department of Encephalopathy, the Second Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province, Nanjing 210017, China |
|
|
Abstract Chronic liver disease refers to a group of clinically common diseases after chronic persistent liver injury. Professor Jinshi summarizes various drug groups according to the characteristics of different diseases and syndromes in a large number of clinical practices: combined Ligustri Lucidi Fructus, Forsythiae Fructus, Ophiopogonis Radix and Atractylodis Macrocephalae Rhizoma to reduce aspartate transaminase; combined Abri Herba, Taraxaci Herba, Prunellae Spica and Schisandrae Chinensis Fructus to reduce alanine transaminase; combined Bupleuri Radix, Aurantii Fructus, Tangerine Pith and Curcumae Longae Rhizoma to reduce alkaline phosphatase and γ-glutamyl transpeptidase; combined Smilacis Glabrae Rhizoma, Phellodendri Chinensis Cortex, Polygoni Cuspidati Rhizoma et Radix and Arnebiae Radix to reduce the amount of chronic viral hepatitis B virus; combined Atractylodis Macrocephalae Rhizoma, Alismatis Rhizoma, Cassiae Semen and Crataegi Fructus to treat nonalcoholic fatty liver disease, and the clinical effect is remarkable. In order to enrich the clinical diagnosis and treatment of chronic liver disease, the author makes a preliminary summary and attached a medical case.
|
|
|
|
|
[1] 王艳欣.慢性肝病的营养评估与治疗[J].实用肝脏病杂志,2018,21(2):317-320.
[2] 王夙静,黄丽华.慢性肝病共发症状管理的研究进展[J].护理与康复,2019,18(4):44-49.
[3] 王海花.女贞子及其有效成分的药理研究[J].临床医药文献电子杂志,2019,6(17):200.
[4] 龙爽,刘绍勇,徐英.痰热清注射液及5种中间体对四氯化碳致急性肝损伤大鼠的保护作用探讨[J].中国实验方剂学杂志,2018,24(11):73-80.
[5] 李庭树,黄锁义.鸡骨草的化学成分、药理作用及临床应用研究进展[J].中国实验方剂学杂志,2019,25(10):226-234.
[6] 梁爽,陶雪,潘炎,等.4种品系五味子木脂素类成分的含量及功效比较[J].吉林大学学报:医学版,2019,45(2):300-306.
[7] 张雯,朱雅迪,张起尧,等.五味子在肝脏疾病防治中的应用及其作用机制研究进展[J].中国中药杂志,2020,45(16):3759-3769.
[8] 吴娟洁,余松,王凯.五酯胶囊治疗慢性乙型肝炎患者顽固性谷丙转氨酶升高临床研究[J].新中医,2019,51(10):134-136.
[9] 程玲.护肝片对利福平导致肝损伤的保护作用及机制研究[D].南京:南京中医药大学,2020.
[10] 乔亚荣.柴胡中皂苷类成分的药代动力学及组织分布研究[D].太原:山西大学,2016.
[11] 吴莉.基于Fxr受体柴胡皂苷类成分的利胆作用机制研究[D].太原:山西大学,2018.
[12] 孙林林,乔利,田振华,等.姜黄化学成分及药理作用研究进展[J].山东中医药大学学报,2019,43(2):207-212.
[13] 范鋆钰.间充质干细胞及姜黄素对PBC中免疫失调和上皮-间质转化的作用及机理研究[D].南京:南京中医药大学,2018.
[14] 闫坤,张欣.土茯苓组方联合常规西药治疗乙型肝炎病毒慢加急性肝衰竭临床研究[J].内蒙古中医药,2017, 36(18):58-59.
[15] 李嘉诚,吴岚,蔡同凯,等.黄柏化学成分及其药理作用研究进展[J].药学实践杂志,2018,36(5):389-391,398.
[16] 梁明辉.中药虎杖的研究进展[J].中国医药指南,2019, 17(10):47,54.
[17] 潘亭.中药虎杖活性成分的分离及抗肝纤维化作用研究[D].广州:南方医科大学,2018.
[18] 陈利,朱风尚,杨长青.非酒精性脂肪性肝炎相关肝细胞癌特征及诊治进展[J].中华消化病与影像杂志:电子版,2020,10(6):267-271.
[19] 黄鸿娜,符燕青,黄晶晶,等.非酒精性脂肪肝中医药治疗进展[J].辽宁中医杂志,2020,47(11):201-203.
[20] 耿高峰.基于网络药理学的加味泽泻汤治疗非酒精性脂肪肝机制研究[D].南京:南京中医药大学,2020.
[21] 封若雨,朱新宇,张苗苗.近五年山楂药理作用研究进展[J].中国中医基础医学杂志,2019,25(5):715-718.
[22] 王颖,蔡永青,黄明春,等.山楂酸对四氯化碳致小鼠急性肝损伤的保护作用及机制研究[J].中国临床药理学与治疗学,2016,21(8):854-858.
[23] 许鹏飞,孙学斌,黄尹琦,等.决明子降脂有效成分的研究进展[J].中华中医药学刊,2018,36(1):150-153.
[24] 赵梓铭,武俊紫,姚政,等.决明子蒽醌苷通过降低Toll样受体4和核因子-κB的表达对非酒精性脂肪肝病大鼠的影响[J].中国临床药理学杂志,2019,35(22):2863-2867.
[25] 王振兴,潘怡,张秀,等.邓中甲治疗肝系病证常用药组选析[J].辽宁中医杂志,2017,44(7):1377-1379. |
|
|
|